NorthLinks Bio

Clinical-stage biopharmaceutical company developing a glycan-targeted, intranasal prophylactic designed to block respiratory virus attachment at the nasal mucosa. Lead investigational candidate completed Phase 1 and a Phase 2 controlled human influenza challenge study with reported reductions in symptomatic influenza and comparable safety to placebo. Platform is based on engineered multivalent carbohydrate-binding modules intended for scalable recombinant manufacture and broad activity across multiple respiratory viruses.